The developments at Holland Capital in 2024 reflect our strong ambitions
Amsterdam/ Düsseldorf, 30th of December 2024 –The developments at Holland Capital in 2024 reflect our strong ambitions. Guided by a focused investment strategy, we continued to actively engage in the high-growth markets of Technology, Healthcare, and Agrifood. Reflecting on a successful year, we completed several key transactions and further strengthened our team.
2024 achievements
- The launch of our fund, Holland Capital Growth and Buy-Out Fund V
- Number of deals in the Netherlands: 5
- Number of add-on acquisitions in the Netherlands: 13
- Number of add-on acquisitions in Germany: 2
- Number of exits: 2
- Number of new colleagues: 4
Sector focus and an entrepreneurial hands-on approach: With specialized sector teams, we focus on the sectors of Healthcare, Technology, and Agrifood, both within the Growth & Buy-out and Venture & Growth segments. We understand the dynamics and opportunities in these sectors and have an extensive network. Holland Capital is not a passive investor; we work closely with management to define and execute strategies. Where needed, our operational team also contributes hands-on to the realization of specific projects within the company.
Which companies would we like to connect with?
- Sector: Technology, Healthcare, and Agrifood
- Positive outlook: Significant growth potential, both autonomous and buy-and-build
- Growth & Buy-out:
- Healthy profitability: cash flow from operations (EBITDA) between EUR 1 – 10m
- Smaller companies: considered as add-on acquisitions for our existing portfolio companies
- Larger companies: considered together with a co-investor
- Venture & Growth:
- Start-ups and scale-ups: EBITDA EUR <1m
- Cash flow negative (in an accelerated growth scenario)
- Revenue EUR 0 – 5m
What to expect from us?
- Flexible approach to transaction structures: We strive to adapt each structure to the needs of the company and its shareholders. Depending on the type of investment, Holland Capital either provides growth capital and/or acquires existing shares. We are flexible regarding the final capital structure: both majority and minority stakes are possible.
- Deal certainty and an efficient process: Thanks to our sector expertise, we are able to quickly assess a business model and put a fair price on the table. Since the partnership with the entrepreneur and/or the management team is the cornerstone of our investment, we devote above-average attention to ensuring the process is completed efficiently, in the right spirit, and with mutual respect for both parties.
- Transparency towards advisors: We appreciate it when advisors involve us early in discussions with entrepreneurs and/or management teams. In such cases, we always ensure that the advisor’s interests are well safeguarded throughout the process. The advisor retains the flexibility to decide whether to represent the sell-side or buy-side in a potential transaction.
About Holland Capital
Holland Capital has been responsibly and successfully investing in promising Dutch and German SMEs with growth ambitions for over 40 years. The team understands entrepreneurship and fosters an open, sustainable, and professional relationship with the management teams of the invested companies, aiming for mutual growth. With offices in Amsterdam and Düsseldorf, Holland Capital focuses on Healthcare, Technology, and Agrifood-Tech sector.
Holland Venture investeert in mobiele accessoire provider Telco Accessories B.V.
Amsterdam, 12 december 2017 – Investeringsmaatschappij Holland Venture investeert met het management in Telco Accessories B.V., internationaal actief op de markt voor mobiele accessoires. De investering stelt de marktleidende organisatie in staat om zowel organisch...
Artificial intelligence als centraal thema tijdens Holland Venture growth session
Amsterdam, 28 november 2017 – De vierde Holland Venture ‘Growth Session’ stond in het teken van Artificial Intelligence (AI). In een interactieve sessie deelde Jörgen Sandig (voormalig CEO Scyfer) zijn ervaringen met de ontwikkeling die Scyfer heeft doorgemaakt....
Medical Artificial Intelligence company Quantib receives capital injection of EUR 4.5 million
Faster and more objective diagnoses by automatic interpretation of MRI and CT scan data Chicago, 27 November 2017 – At the world’s largest radiology conference (RSNA), medical Artificial Intelligence (AI) company Quantib announced today that it secured €4.5mln ($...
Medisch Artificial Intelligence bedrijf Quantib ontvangt kapitaalinjectie van EUR 4,5 miljoen
Snellere en objectievere diagnoses door automatische interpretatie MRI en CT scansChicago, 27 november 2017 – Op ’s werelds grootste radiologie beurs, de RSNA, is vandaag bekend gemaakt dat Investeringsmaatschappij Holland Venture en InnovationQuarter investeren in...
ESDEC zet vol in op innovatie
Deventer, 10 november 2017 - De vraag naar zonne-energie in de Benelux en Europa groeit exponentieel. Door de stijgende motivatie in binnen- en buitenland om te verduurzamen en het succes van de nieuwe generatie montagesystemen voor pv-panelen groeit Esdec sterker dan...
Holland Venture verkoopt haar belang in QSight IT aan KPN
Amsterdam, 3 oktober 2017 - Op 2 oktober zijn de overnamecontracten getekend waarmee Holland Venture en de overige (management) aandeelhouders hun belangen in QSight IT verkopen aan het Nederlandse telecom en ICT-bedrijf KPN. QSight IT is een vooraanstaande...
Amsterdam
Krijn Taconiskade 426
1087 HW Amsterdam
+31 (0) 20 3119411
Düsseldorf
Königsallee 42
40212 Düsseldorf
+49 (0) 211 96290120
Contact
info@hollandcapital.nl